South Korean Parliament Delays Regulatory Bill on Synthetic Nicotine

Feb.12.2025
South Korean Parliament Delays Regulatory Bill on Synthetic Nicotine
South Korean Parliament's committee delays regulation on synthetic nicotine e-cigarettes due to opposition from some members, impacting sales.

According to a report by N.News on February 12th, the South Korean National Assembly's Planning and Finance Committee's Economic and Financial Subcommittee once again postponed the handling of the amendment to the Tobacco Business Act regulating synthetic nicotine e-cigarettes due to opposition from some lawmakers.


During the meeting that day, some lawmakers led by Jung Tae-ho from the Together Democratic Party and Park Dae-chul from the People Power Party mentioned that the regulation of synthetic nicotine e-cigarettes could affect the livelihoods of around 4,000 synthetic nicotine sellers, and therefore opposed the immediate passage of the bill. Some lawmakers argued that the interests of sellers should not be prioritized over public health, but this viewpoint was not accepted. The committee decided to further discuss the bill after consulting with the Ministry of Finance on whether it would lead to price increases and impact sellers' opinions. The tobacco industry believes that with the schedule for further discussion uncertain, the passage of the law is now unlikely in this session of parliament.


Recently, there has been news that a synthetic nicotine e-cigarette company has launched a service allowing customers to order through a mobile app and receive instant delivery, indicating that these products have penetrated the online delivery market. A tobacco industry insider pointed out that further delaying the regulation of synthetic nicotine e-cigarettes will only further threaten public health and expand tax loopholes.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Japan Tobacco seeks retail price hike for Ploom tobacco sticks; EVO and others to rise by 30 yen per pack
Japan Tobacco seeks retail price hike for Ploom tobacco sticks; EVO and others to rise by 30 yen per pack
Japan Tobacco (JT) said it has applied to raise retail prices for its heated tobacco-related products from April 1, 2026, covering 37 variants of Ploom tobacco sticks and with capsules, with most increases at 20–30 yen per pack (about $0.13–$0.19).
Jan.28 by 2FIRSTS.ai
Manchester’s Cheetham Hill Hosts 54 Vape Shops Across Two Streets
Manchester’s Cheetham Hill Hosts 54 Vape Shops Across Two Streets
Cheetham Hill in Greater Manchester has become one of the UK’s most concentrated vape retail clusters, with 54 e-cigarette shops operating along two adjacent streets following a police crackdown on counterfeit goods in the area.
Feb.21
New York’s budget plan would apply a 75% wholesale tax to nicotine pouches, raising projected revenue
New York’s budget plan would apply a 75% wholesale tax to nicotine pouches, raising projected revenue
New York Gov. Kathy Hochul is proposing to tax ZYN nicotine pouches and other nicotine products at the same rate as cigarettes, applying a 75% wholesale tax under her proposed $260 billion state budget.
Jan.21 by 2FIRSTS.ai
Estonia warns of a booming illicit vape market, raising risks for minors and legitimate trade
Estonia warns of a booming illicit vape market, raising risks for minors and legitimate trade
Estonia’s Chamber of Commerce and Industry and the Tax and Customs Board are urging the government to address a thriving illicit vape market that undermines fair competition and makes vapes easily accessible to minors.
Feb.04 by 2FIRSTS.ai
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai